Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $52

Benzinga · 01/05 13:04
Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $64 to $52.